Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

In JAMA, the FDA's Makary and Prasad said they will focus on modernizing review processes and lowering drug costs but don't outright mention precision medicine.

Pfizer’s PFE stock has declined 10.7% so far this year compared with a decrease of 7.7% for the industry. The stock has also ...

Indian pharma grapples headwinds of US pricing reform & Europe’s HTA-driven cost-effectiveness: Akash Kedia: Nandita Vijayasimha, Bengaluru Monday, June 9, 2025, 08:00 Hrs [IST] ...

Fintel reports that on June 6, 2025, Goldman Sachs initiated coverage of Viatris (NasdaqGS:VTRS) with a Neutral ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. We sell ...

Troyen A. Brennan, Harvard University. Biosimilars present a key opportunity to contain the growing cost of biologic drug spending and to make essential medications more affordable. However ...

Introduction The global market for wearable injectors is swiftly growing, propelled by the rising need for self-administration of biologics and ...

Meanwhile, BioNTech itself bought into the category with its takeover of BNT327's developer Biotheus unit last year for what ...

The global biosimilars market growth is driven by increasing number of biosimilar approvals and rising number of biologics going off-patent.A biosimilar is a biological product that is similar to a ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...